Targeted/Emerging Therapies for Metastatic NSCLC
This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Recommend testing for genetic alterations to select novel therapies for patients with metastatic NSCLC
Leora Horn, MD, MSc
Vanderbilt-Ingram Cancer Center
- 0.75 Participation
- 0.69 Nurse
- 0.75 Pharmacist
- 0.75 Physician